Internal Reference Number: FOI_9264
Date Request Received: 04/03/2026 00:00:00
Date Request Replied To: 24/03/2026 00:00:00
This response was sent via: By Email
Request Summary: Non-small cell lung cancer (NSCLC)
Request Category: Researcher
| Question Number 1: How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: 鈥� Atezolizumab (Tecentriq) 鈥� Durvalumab (Imfinzi) 鈥� Nivolumab (Opdivo) 鈥� Pembrolizumab (Keytruda) 鈥� Chemotherapy 鈥� Radiotherapy 鈥� Chemotherapy AND Radiotherapy 鈥� Osimertinib | |
| Answer To Question 1: Please see our response to all questions in the spreadsheet attached. To accompany this answer to question 1 please also see the documents listed below:  13583 - FOI_9264 - Non small cell lung cancer.xlsx | |
| Question Number 2: How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma? | |
| Answer To Question 2: Zero as we don鈥檛 treat melanoma here. | |
| Question Number 3: How many patients has your Trust treated in total in the past 3 months for 鈥� Stage 2 Non-Small Cell Lung Cancer 鈥� Stage 3 Non-Small Cell Lung Cancer | |
| Answer To Question 3: Please see our response to all questions in the spreadsheet attached. | |
| Question Number 4: How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: 鈥� Atezolizumab 鈥� Pembrolizumab monotherapy 鈥� Pembrolizumab monotherapy (subcutaneous injection formulation only) 鈥� Pembrolizumab with chemotherapy 鈥� Pembrolizumab with chemotherapy (subcutaneous injection formulation only) 鈥� Nivolumab 鈥� Osimertinib 鈥� Durvalumab 鈥� Chemotherapy 鈥� Radiotherapy 鈥� Chemotherapy + Radiotherapy | |
| Answer To Question 4: Please see our response to all questions in the spreadsheet attached. | |
| Question Number 5: How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with: 鈥� Chemotherapy 鈥� Radiotherapy 鈥� Chemotherapy + Radiotherapy | |
| Answer To Question 5: Please see our response to all questions in the spreadsheet attached. | |
| Question Number 6: How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: 鈥� Durvalumab | |
| Answer To Question 6: Please see our response to all questions in the spreadsheet attached. | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of 看片软件 Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
